Grifols SA (GRF-P)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 7.170 |
|---|---|
| 52-week range | 6.140 – 8.345 |
| Return, 1 month / 3 months | +10.1% / +4.8% |
| Return, 1 year / 3 years | −11.1% / +1.3% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 29.2% |
| Worst drawdown (1 year) | -23.6% |
| Average daily value traded | 0.58M EUR |
| Dividend yield | 1.3% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Grifols is a Spanish healthcare company that turns donated human plasma into medicines, chiefly immunoglobulins, albumin and clotting-factor therapies used to treat immune deficiencies, bleeding disorders and other chronic conditions. It runs plasma collection centres and fractionation plants, and it also supplies hospitals with diagnostic instruments, transfusion medicine equipment and other pharmacy products. Its customers are hospitals, clinics and healthcare providers, and it is based in Barcelona, Spain.
On this site Grifols SA appears as a stock on the Madrid Stock Exchange (Spain), code GRF-P, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Grifols SA (GRF-P) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 7.170 on 27 October 2026.
Its price-based Market X-Ray is 51 out of 100 (a fair price profile), ranking 126 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 11.1% and over the last three months it rose 4.8%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 56 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 4.1% | ||
| From 52-week high | -12.6% | ||
| Momentum | 60 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 4.8% | ||
| 6-month return | 5.0% | ||
| 12-month return, skipping the last month | -19.3% | ||
| Stability (higher is calmer) | 40 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 29.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -23.6% | ||
| Liquidity | 72 · Strong | Trades actively. | |
| Average daily value traded | 0.58M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 10 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.3% | ||
| Years with dividends | 2 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +5.0% |
|---|---|
| 1 month | +10.1% |
| 3 months | +4.8% |
| 6 months | +5.0% |
| 1 year | −11.1% |
| 3 years | +1.3% |
| 5 years | −36.1% |
Signals
| 50-day / 200-day average | 6.701 / 6.889 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.171 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Jun 2026 | EUR 0.0925 |
| 11 Aug 2025 | EUR 0.1500 |
| 3 Jun 2021 | EUR 0.3745 |
| 26 Oct 2020 | EUR 0.1717 |
| 2 Dec 2019 | EUR 0.2000 |
| 7 Jun 2019 | EUR 0.1553 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.